Back to Search
Start Over
Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure.
- Source :
-
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver [Dig Liver Dis] 2015 Jun; Vol. 47 (6), pp. 518-22. Date of Electronic Publication: 2015 Mar 18. - Publication Year :
- 2015
-
Abstract
- Background: No standard second-line treatments are available for hepatocellular carcinoma patients who fail sorafenib therapy. We assessed the safety and efficacy of metronomic capecitabine after first-line sorafenib failure.<br />Methods: Retrospective analysis of consecutive hepatocellular carcinoma patients receiving metronomic capecitabine between January 2012 and November 2014. The primary end-point was safety, secondary end-point was efficacy, including time-to-progression and overall survival.<br />Results: Twenty-six patients (80% Child-Pugh A, 80% Barcelona Clinic Liver Cancer stage C) received metronomic capecitabine (500 mg/bid). Median treatment duration was 3.2 months (range 0.6-31). Fourteen (53%) patients experienced at least one adverse event. The most frequent drug-related adverse events were bilirubin elevation (23%), fatigue (15%), anaemia (11%), lymphoedema (11%), and hand-foot syndrome (7.6%). Treatment was interrupted in 19 (73%) for disease progression, in 4 (15%) for liver deterioration, and in 1 (3.8%) for adverse event. Disease control was achieved in 6 (23%) patients. Median time-to-progression was 4 months (95% confidence interval 3.2-4.7). Median overall survival was 8 months (95% confidence interval 3.7-12.3).<br />Conclusions: Metronomic capecitabine was well tolerated in hepatocellular carcinoma patients who had been treated with sorafenib. Preliminary data show potential anti-tumour activity with long-lasting disease control in a subgroup of patients that warrants further evaluation in a phase III study.<br /> (Copyright © 2015 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.)
- Subjects :
- Administration, Metronomic
Aged
Carcinoma, Hepatocellular mortality
Female
Humans
Liver Neoplasms mortality
Male
Middle Aged
Niacinamide therapeutic use
Retrospective Studies
Sorafenib
Survival Analysis
Treatment Failure
Antineoplastic Agents therapeutic use
Capecitabine therapeutic use
Carcinoma, Hepatocellular drug therapy
Liver Neoplasms drug therapy
Niacinamide analogs & derivatives
Phenylurea Compounds therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1878-3562
- Volume :
- 47
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
- Publication Type :
- Academic Journal
- Accession number :
- 25861840
- Full Text :
- https://doi.org/10.1016/j.dld.2015.03.010